Home LiteratureArticle Details
PMID: 19641607 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

PloS one ·Vol. 4 ·No. 7 ·2009-07-29 ·Pages e6412

Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH

Abstract

Tumor-infiltrating T cells are associated with survival in epithelial ovarian cancer (EOC), but their functional status is poorly understood, especially relative to the different risk categories and histological subtypes of EOC. Tissue microarrays containing high-grade serous, endometrioid, mucinous and clear cell tumors were analyzed immunohistochemically for the presence of lymphocytes, dendritic cells, neutrophils, macrophages, MHC class I and II, and various markers of activation and inflammation. In high-grade serous tumors from optimally debulked patients, positive associations were seen between intraepithelial cells expressing CD3, CD4, CD8, CD45RO, CD25, TIA-1, Granzyme B, FoxP3, CD20, and CD68, as well as expression of MHC class I and II by tumor cells. Disease-specific survival was positively associated with the markers CD8, CD3, FoxP3, TIA-1, CD20, MHC class I and class II. In other histological subtypes, immune infiltrates were less prevalent, and the only markers associated with survival were MHC class II (positive association in endometrioid cases) and myeloperoxidase (negative association in clear cell cases). Host immune responses to EOC vary widely according to histological subtype and the extent of residual disease. TIA-1, FoxP3 and CD20 emerge as new positive prognostic factors in high-grade serous EOC from optimally debulked patients.

MeSH Terms
Antigens, CD20/immunology B-Lymphocytes/immunology Biomarkers, Tumor/immunology Female Forkhead Transcription Factors/immunology Humans Immunohistochemistry Middle Aged Ovarian Neoplasms/immunology,pathology Poly(A)-Binding Proteins/immunology Prognosis Survival Analysis T-Cell Intracellular Antigen-1 Tissue Array Analysis
Chemicals
Antigens, CD20 Biomarkers, Tumor FOXP3 protein, human Forkhead Transcription Factors Poly(A)-Binding Proteins T-Cell Intracellular Antigen-1 TIA1 protein, human
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Milne Katy
Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada.
Köbel Martin
Kalloger Steven E
Barnes Rebecca O
Gao Dongxia
Gilks C Blake
Watson Peter H
Nelson Brad H
References (136)
136 references, click to expand
  1. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
    J Clin Oncol. 2009 Jan 10;27(2):186-92 PMID: 19064967
  2. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.
    Cancer Res. 2007 Sep 15;67(18):8900-5 PMID: 17875732
  3. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.
    Clin Cancer Res. 2007 Jul 15;13(14):4139-45 PMID: 17634541
  4. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.
    Nat Med. 2001 Dec;7(12):1339-46 PMID: 11726975
  5. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
    Nature. 2006 May 11;441(7090):235-8 PMID: 16648838
  6. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Gynecol Oncol. 2008 Feb;108(2):415-20 PMID: 18037158
  7. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.
    Cancer Res. 2005 Jun 15;65(12):5020-6 PMID: 15958543
  8. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.
    Immunity. 2006 Feb;24(2):179-89 PMID: 16473830
  9. The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice.
    J Immunol. 1988 Jun 1;140(11):3773-8 PMID: 2453554
  10. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.
    Am J Pathol. 1997 May;150(5):1723-34 PMID: 9137096
  11. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans.
    Hum Immunol. 2005 Jan;66(1):13-20 PMID: 15620457
  12. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.
    Blood. 2009 Mar 19;113(12):2765-3775 PMID: 19096012
  13. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
    Gynecol Oncol. 2008 May;109(2):215-9 PMID: 18314181
  14. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells.
    Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12659-64 PMID: 11606714
  15. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.
    Br J Haematol. 2007 May;137(4):364-73 PMID: 17456059
  16. OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines.
    Trends Immunol. 2002 Feb;23(2):102-9 PMID: 11929124
  17. Regulatory T cells in ovarian cancer: biology and therapeutic potential.
    Am J Reprod Immunol. 2005 Dec;54(6):369-77 PMID: 16305662
  18. Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.
    Cancer Immunol Immunother. 2007 Oct;56(10):1645-52 PMID: 17387473
  19. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
    J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 PMID: 12953086
  20. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
    N Engl J Med. 2003 Jan 16;348(3):203-13 PMID: 12529460
  21. Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes.
    J Nippon Med Sch. 2003 Feb;70(1):40-4 PMID: 12646975
  22. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes.
    J Immunol. 1987 May 1;138(9):2848-56 PMID: 2952725
  23. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes.
    J Immunol. 1987 Feb 15;138(4):1051-5 PMID: 3100626
  24. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.
    Cancer Res. 2005 May 15;65(10):3998-4004 PMID: 15899788
  25. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Leuk Lymphoma. 2000 Jul;38(3-4):317-26 PMID: 10830738
  26. Transient T cell depletion causes regression of melanoma metastases.
    J Transl Med. 2008 Mar 11;6:12 PMID: 18334033
  27. Expansion of activated human naïve T-cells precedes effector function.
    Clin Exp Immunol. 2002 Dec;130(3):432-40 PMID: 12452833
  28. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast.
    Mod Pathol. 1999 Nov;12(11):1050-6 PMID: 10574602
  29. Coordination of early protective immunity to viral infection by regulatory T cells.
    Science. 2008 May 30;320(5880):1220-4 PMID: 18436744
  30. Natural regulatory T cells: mechanisms of suppression.
    Trends Mol Med. 2007 Mar;13(3):108-16 PMID: 17257897
  31. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.
    Am J Clin Pathol. 2006 Mar;125(3):451-8 PMID: 16613351
  32. Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression.
    Mod Pathol. 2009 Mar;22(3):373-84 PMID: 18997734
  33. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Cancer Res. 2001 Jun 15;61(12):4766-72 PMID: 11406550
  34. The impact of T-cell immunity on ovarian cancer outcomes.
    Immunol Rev. 2008 Apr;222:101-16 PMID: 18363996
  35. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
    Clin Cancer Res. 2008 Dec 1;14(23):7667-73 PMID: 19047092
  36. Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.
    J Immunother. 2008 Feb-Mar;31(2):189-98 PMID: 18481388
  37. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
    J Clin Invest. 2005 Dec;115(12):3623-33 PMID: 16308572
  38. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma.
    Ann Oncol. 2005 Apr;16(4):590-6 PMID: 15699022
  39. B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes.
    J Exp Med. 1993 Mar 1;177(3):679-90 PMID: 8436906
  40. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
    Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6659-64 PMID: 16617117
  41. Expression of CD68 in non-myeloid cell types.
    Scand J Immunol. 2008 May;67(5):453-63 PMID: 18405323
  42. FOXP3: not just for regulatory T cells anymore.
    Eur J Immunol. 2007 Jan;37(1):21-3 PMID: 17183612
  43. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas.
    Cancer Res. 2003 Jun 15;63(12):3275-80 PMID: 12810659
  44. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.
    Eur J Immunol. 2007 Jan;37(1):129-38 PMID: 17154262
  45. Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response.
    Int Immunol. 1995 Aug;7(8):1353-62 PMID: 7495742
  46. Transient regulatory T-cells: a state attained by all activated human T-cells.
    Clin Immunol. 2007 Apr;123(1):18-29 PMID: 17185041
  47. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
    Clin Cancer Res. 2005 Dec 1;11(23):8326-31 PMID: 16322292
  48. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer.
    Br J Cancer. 2008 Jan 15;98(1):148-53 PMID: 18087278
  49. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.
    J Clin Invest. 2003 Nov;112(9):1437-43 PMID: 14597769
  50. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer.
    Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10 PMID: 18832156
  51. Macrophage polarization in tumour progression.
    Semin Cancer Biol. 2008 Oct;18(5):349-55 PMID: 18467122
  52. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
    Clin Cancer Res. 2006 Jan 15;12(2):465-72 PMID: 16428488
  53. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
    Nat Med. 2003 May;9(5):562-7 PMID: 12704383
  54. Expression of IL-17 mRNA in ovarian cancer.
    Biochem Biophys Res Commun. 2001 Apr 6;282(3):735-8 PMID: 11401524
  55. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.
    J Pathol. 2002 Mar;196(3):254-65 PMID: 11857487
  56. B-cell targeting in rheumatoid arthritis and other autoimmune diseases.
    Nat Rev Immunol. 2006 May;6(5):394-403 PMID: 16622478
  57. Identification of IL-17-producing FOXP3+ regulatory T cells in humans.
    Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4793-8 PMID: 19273860
  58. Interferon-gamma expression is an independent prognostic factor in ovarian cancer.
    Am J Obstet Gynecol. 2004 Nov;191(5):1598-605 PMID: 15547530
  59. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
    Int J Cancer. 2007 Jun 15;120(12):2723-33 PMID: 17315189
  60. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study.
    J Clin Oncol. 2006 Oct 1;24(28):4626-33 PMID: 16954517
  61. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
    Clin Cancer Res. 2008 Aug 15;14(16):5220-7 PMID: 18698040
  62. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Cell Immunol. 1996 Dec 15;174(2):116-28 PMID: 8954611
  63. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.
    Haematologica. 2009 Jan;94(1):70-7 PMID: 19059937
  64. Class I histocompatibility antigen expression: a prognostic factor for aneuploid ovarian cancers.
    Gynecol Oncol. 1990 Sep;38(3):458-61 PMID: 2227561
  65. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Gynecol Oncol. 2007 Jul;106(1):75-81 PMID: 17433425
  66. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.
    Leuk Lymphoma. 2005 Nov;46(11):1581-91 PMID: 16236613
  67. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
    Hum Pathol. 2008 Aug;39(8):1239-51 PMID: 18602670
  68. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 PMID: 16344461
  69. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast.
    Virchows Arch. 2005 Jan;446(1):10-4 PMID: 15660281
  70. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  71. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells.
    J Immunol. 2006 Mar 15;176(6):3498-506 PMID: 16517718
  72. FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies.
    J Clin Pathol. 2008 Aug;61(8):969-71 PMID: 18413654
  73. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.
    Blood. 2007 Dec 15;110(13):4319-30 PMID: 17848619
  74. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.
    Am J Pathol. 2002 Mar;160(3):893-903 PMID: 11891188
  75. Delivering the kiss of death: progress on understanding how perforin works.
    Curr Opin Immunol. 2007 Jun;19(3):301-8 PMID: 17433871
  76. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers.
    Breast Cancer Res Treat. 2007 Aug;104(2):129-44 PMID: 17393302
  77. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
    Blood. 2008 Aug 1;112(3):610-8 PMID: 18519811
  78. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.
    Clin Cancer Res. 2008 Jun 1;14(11):3372-9 PMID: 18519766
  79. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years.
    Gynecol Oncol. 2008 Jan;108(1):106-11 PMID: 17945335
  80. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.
    Blood. 2008 Sep 15;112(6):2340-52 PMID: 18617638
  81. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.
    Cancer Res. 2008 Apr 15;68(8):3001-9 PMID: 18413770
  82. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells.
    Trends Immunol. 2006 Dec;27(12):541-4 PMID: 17045841
  83. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
    Blood. 2008 Dec 15;112(13):4953-60 PMID: 18820132
  84. FOXP3 defines regulatory T cells in human tumor and autoimmune disease.
    Cancer Res. 2009 May 1;69(9):3995-4000 PMID: 19383912
  85. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.
    J Clin Oncol. 2006 Nov 1;24(31):5052-9 PMID: 17033038
  86. Regulatory T cells in health and disease.
    Cytokine. 2008 Sep;43(3):395-401 PMID: 18722786
  87. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
    J Immunol. 1999 Dec 1;163(11):6251-60 PMID: 10570318
  88. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.
    Blood. 2007 Oct 15;110(8):2983-90 PMID: 17644734
  89. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.
    J Immunol. 2006 Apr 15;176(8):5023-32 PMID: 16585599
  90. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo.
    J Immunol. 1995 Oct 15;155(8):3734-41 PMID: 7561077
  91. Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.
    Semin Oncol. 2000 Jun;27(3 Suppl 7):47-9 PMID: 10952127
  92. A critical role for B cells in the development of memory CD4 cells.
    J Immunol. 2000 Nov 15;165(10):5558-65 PMID: 11067910
  93. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.
    Nat Med. 2008 Jan;14(1):28-36 PMID: 18157142
  94. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
    Cancer Immunol Immunother. 2009 Mar;58(3):449-59 PMID: 18791714
  95. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
    Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 PMID: 17360651
  96. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Oncol Rep. 2005 Jun;13(6):1153-8 PMID: 15870936
  97. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
    Blood. 2006 Nov 1;108(9):2957-64 PMID: 16825494
  98. Foxp3 expression in human cancer cells.
    J Transl Med. 2008 Apr 22;6:19 PMID: 18430198
  99. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.
    Cancer Res. 2007 Sep 1;67(17):8344-50 PMID: 17804750
  100. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level.
    Eur J Immunol. 2005 Jun;35(6):1681-91 PMID: 15902688
  101. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
    J Clin Oncol. 2003 Sep 1;21(17):3194-200 PMID: 12860964
  102. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.
    J Immunol. 2002 Aug 15;169(4):1829-36 PMID: 12165506
  103. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.
    Clin Cancer Res. 2005 Feb 15;11(4):1467-73 PMID: 15746048
  104. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
    J Immunol. 2007 Oct 1;179(7):4919-28 PMID: 17878392
  105. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
    PLoS Med. 2008 Dec 2;5(12):e232 PMID: 19053170
  106. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.
    Int Immunol. 2007 Apr;19(4):345-54 PMID: 17329235
  107. Regulatory T cells, tumour immunity and immunotherapy.
    Nat Rev Immunol. 2006 Apr;6(4):295-307 PMID: 16557261
  108. Post-transcriptional regulation of proinflammatory proteins.
    J Leukoc Biol. 2004 Jul;76(1):42-7 PMID: 15075353
  109. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.
    Clin Cancer Res. 2007 Jun 15;13(12):3591-6 PMID: 17575223
  110. Is FOXP3 a bona fide marker for human regulatory T cells?
    Eur J Immunol. 2008 Apr;38(4):925-7 PMID: 18395862
  111. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes.
    J Immunol. 2005 Aug 15;175(4):2278-85 PMID: 16081796
  112. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells.
    J Immunol. 2002 Sep 1;169(5):2701-11 PMID: 12193744
  113. Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast.
    Eur J Gynaecol Oncol. 2002;23(5):433-6 PMID: 12440819
  114. Immune prognostic factors in ovarian cancer: lessons from translational research.
    Dis Markers. 2007;23(5-6):445-52 PMID: 18057527
  115. TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.
    Mod Pathol. 2000 Jan;13(1):52-5 PMID: 10658910
  116. Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex.
    Front Biosci. 2008 May 01;13:3986-4001 PMID: 18508492
  117. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells.
    Blood. 2009 Jan 22;113(4):827-36 PMID: 18941119
  118. Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice.
    Eur J Immunol. 1981 Dec;11(12):964-8 PMID: 6173237
  119. Differentiation and function of Th17 T cells.
    Curr Opin Immunol. 2007 Jun;19(3):281-6 PMID: 17433650
  120. A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes.
    J Immunol. 2003 Feb 1;170(3):1443-51 PMID: 12538706
  121. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo.
    Cancer Res. 2008 Sep 15;68(18):7520-9 PMID: 18794140
  122. Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma.
    Int J Clin Oncol. 2004 Feb;9(1):42-6 PMID: 15162825
  123. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.
    Cancer Immunol Immunother. 2008 Jan;57(1):97-106 PMID: 17602225
  124. B-lymphocyte contributions to human autoimmune disease.
    Immunol Rev. 2008 Jun;223:284-99 PMID: 18613843
  125. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Gynecol Oncol. 2008 Sep;110(3):365-73 PMID: 18571704
  126. IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3.
    Eur J Immunol. 2008 Jun;38(6):1621-30 PMID: 18493981
  127. The humoral immune system has a key prognostic impact in node-negative breast cancer.
    Cancer Res. 2008 Jul 1;68(13):5405-13 PMID: 18593943
  128. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Clin Cancer Res. 2008 Aug 15;14(16):5198-208 PMID: 18698038
  129. Identification and functional characterization of a TIA-1-related nucleolysin.
    Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8681-5 PMID: 1326761
  130. Revisiting the prognostic value of regulatory T cells in patients with cancer.
    J Clin Oncol. 2009 Jul 1;27(19):e5-6; author reply e7 PMID: 19470910
  131. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t.
    Proc Natl Acad Sci U S A. 2009 May 26;106(21):8635-40 PMID: 19439651
  132. Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.
    Int J Cancer. 2009 May 15;124(10):2353-60 PMID: 19170204
  133. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
    J Immunother. 2009 Feb-Mar;32(2):101-8 PMID: 19238008
  134. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
    Mod Pathol. 2009 Mar;22(3):393-402 PMID: 19060844
  135. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
    J Exp Med. 2006 Apr 17;203(4):871-81 PMID: 16606666
  136. Ovarian cancer: epidemiology, biology, and prognostic factors.
    Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 PMID: 10883018
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
DOI
10.1371/journal.pone.0006412
Published
2009-07-29
Epub
2009-00-29
Pages
e6412
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC2712762
Subset
IM
Corrections
ErratumIn
-
External Links
PubMed source DOI: 10.1371/journal.pone.0006412 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2